Evidence map›Paper›PMID 40222940›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Delayed Hepatitis B Virus Reactivation at 33 Months after the Completion of Rituximab-based Chemotherapy.

Banri Ogawa, Toshiro Kamoshida, Asaji Yamamoto, Yuji Yamaguchi, Yukako Hamano, Haruka Okawara, Atsushi Okawara, Nobushige Kakinoki, Shinji Hirai

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Banri OgawaDepartment of Gastroenterology, Hitachi General Hospital, Japan.
Toshiro KamoshidaDepartment of Gastroenterology, Hitachi General Hospital, Japan.
Asaji YamamotoDepartment of Gastroenterology, Hitachi General Hospital, Japan.
Yuji YamaguchiDepartment of Gastroenterology, Hitachi General Hospital, Japan.
Yukako HamanoDepartment of Gastroenterology, Hitachi General Hospital, Japan.
Haruka OkawaraDepartment of Gastroenterology, Hitachi General Hospital, Japan.
Atsushi OkawaraDepartment of Gastroenterology, Hitachi General Hospital, Japan.
Nobushige KakinokiDepartment of Gastroenterology, Hitachi General Hospital, Japan.
Shinji HiraiDepartment of Gastroenterology, Hitachi General Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a case of hepatitis B virus (HBV) reactivation in a female patient in her 70s with isolated anti-hepatitis B core (IAHBc) antibodies [HB surface antigen (HBsAg)-negative, HB surface antibody (HBsAb)-negative, and HB core antibody (HBcAb)-positive], receiving rituximab-based chemotherapy for follicular lymphoma. Her serum HBV DNA was negative. The patient was treated with rituximab for 21 months, and 33 months after completion of treatment, her HBV DNA level increased to 5.1 Log IU/mL, and the patient developed hepatic failure. Tenofovir alafenamide fumarate treatment was initiated for HBV reactivation, and DNA was not detected 9 months later.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHepatitis BHepatitis B virusLymphoma, FollicularRituximabVirus ActivationAgedDNA, ViralFemaleHumansTenofovirTime FactorsDNA, ViralRituximabTenofovirHBV reactivationrituximabtenofovir alafenamide

Identifiers

PMID40222940
PMCPMC12589165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.